<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02605044</url>
  </required_header>
  <id_info>
    <org_study_id>AB12006</org_study_id>
    <nct_id>NCT02605044</nct_id>
  </id_info>
  <brief_title>Study to Compare the Efficacy and Safety of Masitinib in Combination With FOLFIRI to Placebo in Combination With FOLFIRI in Second Line Treatment of Patients With Metastatic Colorectal Cancer</brief_title>
  <official_title>A Prospective, Multicenter, Randomized, Double Blind, Placebo-controlled, 2-parallel Groups, Phase 3 Study to Compare the Efficacy and Safety of Masitinib in Combination With FOLFIRI (Irinotecan, 5-fluorouracil and Folinic Acid) to Placebo in Combination With FOLFIRI in Second Line Treatment of Patients With Metastatic Colorectal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AB Science</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AB Science</source>
  <brief_summary>
    <textblock>
      The objective is to compare the efficacy and safety of masitinib in combination with FOLFIRI
      ( irinotecan, 5-fluorouracil and folinic acid) to placebo in combination with FOLFIRI in
      second line treatment of patients.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2014</start_date>
  <completion_date type="Anticipated">June 2018</completion_date>
  <primary_completion_date type="Anticipated">April 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall survival</measure>
    <time_frame>untill progression, within 100 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Survival rate</measure>
    <time_frame>untill progression, within 100 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tumor assessment (PFS)</measure>
    <time_frame>untill progression, within 100 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tumor assessment (TTP)</measure>
    <time_frame>uuntill progression, within 100 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tumor assessment (Best Response)</measure>
    <time_frame>uuntill progression, within 100 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life (ECOG)</measure>
    <time_frame>untill progression, within 100 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life (analgesic intake)</measure>
    <time_frame>untill progression, within 100 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacogenomic assessment (Gene typing)</measure>
    <time_frame>untill progression, within 100 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety profile (all adverse effects)</measure>
    <time_frame>untill progression, within 100 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">550</enrollment>
  <condition>2nd Line Metastatic Colorectal Cancer</condition>
  <arm_group>
    <arm_group_label>Masitinib + FOLFIRI</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>masitinib + FOLFIRI</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo + FOLFIRI</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo + FOLFIRI</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Masitinib (AB1010)</intervention_name>
    <arm_group_label>Masitinib + FOLFIRI</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FOLFIRI</intervention_name>
    <arm_group_label>Masitinib + FOLFIRI</arm_group_label>
    <arm_group_label>Placebo + FOLFIRI</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient with non-resectable metastatic colorectal cancer

          -  Metastatic disease not amenable to surgical resection

          -  Patient in second line treatment after progression according to RECIST criteria

          -  Patient with measurable lesions according to RECIST criteria (version 1.1)

          -  Patient eligible for a standard second line treatment with FOLFIRI

          -  Patient with ECOG ≤ 2

          -  Patient with adequate organ function

          -  Patient with life expectancy &gt; 3 months

          -  Female or male patient ≥ 18

          -  Patient weight &gt; 40 kg and BMI &gt; 18

        Exclusion Criteria:

          -  Patient who cannot receive FOLFIRI

          -  More than 1 prior chemotherapy regimens for metastatic colorectal cancer

          -  Pregnant, intent to be pregnant, or nursing female patient

          -  Patient with any chronic inflammatory bowel disease

          -  Patient treated for a cancer other than colorectal cancer within five years before
             enrollment

          -  Patient with an hepatic involvement &gt; 50%

          -  Patient with active central nervous system (CNS) metastasis or history of CNS
             metastases

          -  Patient with an active infection

          -  Patient presenting with cardiac disorders

          -  Any previous treatment with an investigational agent or chemotherapy or biological
             agent within four weeks prior to baseline.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Olena Vlasyuk, MD</last_name>
    <phone>+331472099783</phone>
    <email>olena.vlasyuk@ab.science.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hospital</name>
      <address>
        <city>City</city>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Olena Vlasyuk, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>November 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 5, 2015</study_first_submitted>
  <study_first_submitted_qc>November 13, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 16, 2015</study_first_posted>
  <last_update_submitted>November 13, 2015</last_update_submitted>
  <last_update_submitted_qc>November 13, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 16, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

